Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 11/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5329840 | 1.00 | PTGS1 (0.47) | PTGS1KCNH2VNN1CA1CA2 | |
| Ethylenediamine SCHEMBL28334089 | 0.93 | PTGS1 (0.43) | PTGS1KCNH2VNN1 | |
| SCHEMBL18697963 | 0.80 | CA1 (0.37) | PTGS1KCNH2CA1CA2 | |
| Pantoic Acid SCHEMBL11561456 | 0.78 | PTGS1 (0.42) | PTGS1KCNH2VNN1 | |
| Pantoic Acid SCHEMBL11561453 | 0.78 | PTGS1 (0.42) | PTGS1KCNH2VNN1 | |
| Pantoic Acid SCHEMBL213982 | 0.77 | PTGS1 (0.48) | PTGS1KCNH2VNN1 | |
| Pantoic Acid SCHEMBL213981 | 0.77 | PTGS1 (0.48) | PTGS1KCNH2VNN1 | |
| Pantoic Acid SCHEMBL29112230 | 0.77 | PTGS1 (0.48) | PTGS1KCNH2VNN1 | |
| SCHEMBL10074938 | 0.77 | PTGS1 (0.48) | PTGS1KCNH2VNN1 | |
| Pantoic Acid SCHEMBL7781736 | 0.77 | PTGS1 (0.48) | PTGS1KCNH2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114945366-B | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-112964625-B | Cell population analysis | 英国质谱公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023123046-A1 | COMPOSITION FOR CARING FOR THE SKIN | L'OREAL (FR) | 2023-07-06 | — | — | WO | disclosed |
| WO-2020111229-A1 | DRUG DELIVERY SYSTEM USING SOLUTION | 国立大学法人京都大学 | 2020-06-04 | — | — | WO | disclosed |
| US-20190224170-A1 | THERAPIES AND METHODS TO TREAT INFLAMMATORY GASTROINTESTINAL DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-25 | — | — | US | disclosed |
| EP-3236938-B1 | ORAL TOPICAL AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FLURBIPROFEN AND DEXPANTHENOL | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2019-03-27 | — | — | EP | disclosed |
| US-9670153-B2 | Compositions and methods for the treatment of inflammation and lipid disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2017-06-06 | — | — | US | disclosed |
| US-9670153-B2 | Compositions and methods for the treatment of inflammation and lipid disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2017-06-06 | — | — | US | disclosed |
| US-9193674-B2 | Process for the preparation of aminoacrylic acid derivatives | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-11-24 | — | — | US | disclosed |
| US-9056851-B2 | Thiolactone antibiotics | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150057347-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND LIPID DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-02-26 | — | — | US | disclosed |
| US-20150057347-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND LIPID DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-02-26 | — | — | US | disclosed |
| US-20140113941-A1 | THIOLACTONE ANTIBIOTICS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-04-24 | — | — | US | disclosed |
| WO-2012135027-A2 | THIOLACTONE ANTIBIOTICS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8119364-B2 | Methods for generating analogs of coenzyme A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100304430-A1 | Methods for Generating Analogs of Coenzyme A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057347-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND LIPID DISORDERS | FABP2, SLC10A2, LIPC | PTGS1 341/4885KCNH2 1794/4885VNN1 1154/4885 |
| US-20140113941-A1 | THIOLACTONE ANTIBIOTICS | TTL, UBE2L3, TST | PTGS1 2924/4885KCNH2 804/4885VNN1 2152/4885 |
| US-20190224170-A1 | THERAPIES AND METHODS TO TREAT INFLAMMATORY GASTROINTESTINAL DISEASES AND DISORDERS | FABP2, VNN1, APC | PTGS1 71/4885KCNH2 4611/4885VNN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.